Get the Stockscreener App
8.82
1.72%
0.13
Applied Therapeutics Inc stock is traded at $8.82, with a volume of 968.69K.
It is up +1.72% in the last 24 hours and down -1.35% over the past month.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
See More
Previous Close:
$8.69
Open:
$8.68
24h Volume:
968.69K
Relative Volume:
0.39
Market Cap:
$1.01B
Revenue:
-
Net Income/Loss:
$-119.76M
P/E Ratio:
-7.9459
EPS:
-1.11
Net Cash Flow:
$-55.17M
1W Performance:
-13.68%
1M Performance:
-1.35%
6M Performance:
+110.96%
1Y Performance:
+344.19%
1-Day Range:
$8.60
$8.97
1-Week Range:
$8.60
$10.12
52-Week Range:
$1.79
$10.62
Applied Therapeutics Inc Stock (APLT) Company Profile
Name
Applied Therapeutics Inc
Sector
Industry
Phone
212-220-9226
Address
545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY
Compare APLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| APLT | 8.83 | 1.01B | 0 | -119.76M | -55.17M | -1.11 |
| VRTX | 467.39 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 761.21 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 566.22 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 230.85 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.60 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-04-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Aug-27-21 | Downgrade | Goldman | Neutral → Sell |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Oct-08-20 | Initiated | Truist | Buy |
| Apr-22-20 | Initiated | Goldman | Buy |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jun-10-19 | Initiated | Citigroup | Buy |
| Jun-10-19 | Initiated | Cowen | Outperform |
| Jun-10-19 | Initiated | Robert W. Baird | Outperform |
View All
Applied Therapeutics Inc Stock (APLT) Latest News
Applied Therapeutics, Inc. (NASDAQ:APLT) Sees Large Drop in Short Interest - MarketBeat
Perceptive Advisors LLC Expands Stake in Applied Therapeutics Inc - GuruFocus.com
Alyeska Investment Group, L.P. Increases Stake in Applied Therap - GuruFocus.com
Janus Henderson Group PLC's Strategic Investment in Applied Ther - GuruFocus.com
Vestal Point Capital's Strategic Reduction in Applied Therapeuti - GuruFocus.com
Applied Therapeutics (NASDAQ:APLT) Sets New 1-Year HighWhat's Next? - MarketBeat
Analysts Set Applied Therapeutics, Inc. (NASDAQ:APLT) PT at $12.50 - Defense World
Applied Therapeutics, Inc. (NASDAQ:APLT) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
How To Trade (APLT) - Stock Traders Daily
Applied Therapeutics Inc (APLT) Quarterly 10-Q Report - Quartzy
APLTApplied Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Applied Therapeutics Inc (APLT) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
Applied Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times
APLT (Applied Therapeutics) Cash From Other Investing Activities : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
Applied Therapeutics to Present at the 2024 UBS Global Healthcare Conference - GlobeNewswire
Applied Therapeutics To Present At The 2024 UBS Global Healthcare Conference - Barchart
Applied Therapeutics stock hits 52-week high at $9.41 By Investing.com - Investing.com Canada
Applied Therapeutics (NASDAQ:APLT) Reaches New 1-Year HighHere's What Happened - MarketBeat
Applied Therapeutics stock hits 52-week high at $9.41 - Investing.com
US FDA’s November Goal Dates Cannot Elevate 2024’s Novel Approvals To 2023 Levels - Citeline News & Insights
Seven PDUFA dates on FDA’s November calendar - BioCentury
Biotech Stocks Facing FDA Decision In November 2024 - RTTNews
Applied Therapeutics (APLT) Upgraded to Buy: Here's What You Should Know - MSN
ImmunityBio (IBRX) Soars 26.4%: Is Further Upside Left in the Stock? - MSN
Is Applied Therapeutics (APLT) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Trigg Minerals Announces Key AGM Resolutions - MSN
Trading (APLT) With Integrated Risk Controls - Stock Traders Daily
Applied Therapeutics, Inc. (NASDAQ:APLT) Short Interest Update - MarketBeat
OncoSil Medical Plans Major Stock Issuance - MSN
Applied Therapeutics (NASDAQ:APLT) versus Ironwood Pharmaceuticals (NASDAQ:IRWD) Head-To-Head Analysis - Defense World
Hennion & Walsh Asset Management Inc. Has $2.26 Million Holdings in Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
Applied Therapeutics (NASDAQ:APLT) Shares Down 4.9%Here's What Happened - MarketBeat
William Blair Issues Pessimistic Outlook for APLT Earnings - Defense World
Q2 EPS Estimate for Applied Therapeutics Cut by Analyst - MarketBeat
Sharps Technology files to sell 259,092 shares of common stock for holders - MSN
Ardmore Shipping leads tanker stocks lower as Stifel downgrades, seeing softer rates - MSN
Invesco BulletShares 2024 High Yield Corporate Bond ETF declares monthly distribution of $0.1100 - MSN
Is the Options Market Predicting a Spike in American Healthcare REIT, Inc. (AHR) Stock? - MSN
Waste Connections Q3 2024 Earnings Preview - MSN
APLT Stock Soars 69% on Positive Update on Galactosemia Drug NDA - MSN
Viking Therapeutics Stock: Buy or Sell Before Q3 Earnings? - MSN
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views? - MSN
Analysts Set Applied Therapeutics, Inc. (NASDAQ:APLT) Price Target at $12.50 - Defense World
Applied Therapeutics (NASDAQ:APLT) Trading Down 2.2%Here's What Happened - MarketBeat
There is no doubt that Applied Therapeutics Inc (APLT) ticks all the boxes. - SETE News
Applied Therapeutics Inc’s Market Journey: Closing Strong at 9.14, Up 2.81 - The Dwinnex
Varonis Systems Inc [VRNS] Investment Appeal on the Rise - Knox Daily
Applied Therapeutics Inc (APLT) gets rating Initiated from William Blair - Knox Daily
Wedbush’s latest rating for SYRE stock - Knox Daily
Omega Healthcare Investors, Inc.’s latest rating changes from various analysts - Knox Daily
Analysts review Liberty Energy Inc’s rating - Knox Daily
Applied Therapeutics Inc Stock (APLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Applied Therapeutics Inc Stock (APLT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Perfetti Riccardo | Chief Medical Officer |
Aug 22 '24 |
Sale |
5.83 |
22,681 |
132,230 |
986,853 |
| Shendelman Shoshana | President and CEO |
Aug 13 '24 |
Sale |
6.18 |
357,423 |
2,208,874 |
4,810,430 |
| Shendelman Shoshana | President and CEO |
Aug 12 '24 |
Sale |
5.98 |
300,000 |
1,794,000 |
5,167,853 |
| Shendelman Shoshana | President and CEO |
Aug 14 '24 |
Sale |
5.93 |
119,591 |
709,175 |
4,690,839 |
3.39%
0.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):